Evidence map›Paper›PMID 38309259›Full record

ArticleCell host & microbe2024

The live biotherapeutic SYNB1353 decreases plasma methionine via directed degradation in animal models and healthy volunteers.

Mylène Perreault, Jillian Means, Erik Gerson, Michael James, Sean Cotton, Christopher G Bergeron, Mark Simon, Dylan Alexander Carlin, Nathan Schmidt, Theodore C Moore and 8 more

Open access · hybridAbstract readComment
PubMed Publisher
In one paragraph

Article in Cell host & microbe, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
13.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Review
  3. Methionine restriction and mimetics to ameliorate human aging and disease.Trends in endocrinology and metabolism: TEM · 2026
    Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Bacterial live therapeutics for human diseases.Molecular systems biology · 2024
    Review
  13. Review
  14. Diagnosing and engineering gut microbiomes.EMBO molecular medicine · 2024
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Mylène PerreaultSynlogic, Inc., Cambridge, MA 02142, USA. Electronic address: mylene@synlogictx.com.
Jillian MeansSynlogic, Inc., Cambridge, MA 02142, USA.
Erik GersonSynlogic, Inc., Cambridge, MA 02142, USA.
Michael JamesSynlogic, Inc., Cambridge, MA 02142, USA.
Sean CottonSynlogic, Inc., Cambridge, MA 02142, USA.
Christopher G BergeronSynlogic, Inc., Cambridge, MA 02142, USA.
Mark SimonGinkgo Bioworks, Boston, MA 02210, USA.
Dylan Alexander CarlinGinkgo Bioworks, Boston, MA 02210, USA.
Nathan SchmidtGinkgo Bioworks, Boston, MA 02210, USA.
Theodore C MooreGinkgo Bioworks, Boston, MA 02210, USA.
Julie BlasbalgSynlogic, Inc., Cambridge, MA 02142, USA.
Neal SondheimerSynlogic, Inc., Cambridge, MA 02142, USA.
Kenneth Ndugga-KabuyeSynlogic, Inc., Cambridge, MA 02142, USA.
William S DenneyHuman Predictions LLC, Boston, MA 02115, USA.
Vincent M IsabellaSynlogic, Inc., Cambridge, MA 02142, USA.
David LubkowiczSynlogic, Inc., Cambridge, MA 02142, USA.
Aoife BrennanSynlogic, Inc., Cambridge, MA 02142, USA.
David L HavaSynlogic, Inc., Cambridge, MA 02142, USA.
Synlogic (United States) · USGinkgo BioWorks (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Methionine is an essential proteinogenic amino acid, but its excess can lead to deleterious effects. Inborn errors of methionine metabolism resulting from loss of function in cystathionine β-synthase (CBS) cause classic homocystinuria (HCU), which is managed by a methionine-restricted diet. Synthetic biotics are gastrointestinal tract-targeted live biotherapeutics that can be engineered to replicate the benefits of dietary restriction. In this study, we assess whether SYNB1353, an E. coli Nissle 1917 derivative, impacts circulating methionine and homocysteine levels in animals and healthy volunteers. In both mice and nonhuman primates (NHPs), SYNB1353 blunts the appearance of plasma methionine and plasma homocysteine in response to an oral methionine load. A phase 1 clinical study conducted in healthy volunteers subjected to an oral methionine challenge demonstrates that SYNB1353 is well tolerated and blunts plasma methionine by 26%. Overall, SYNB1353 represents a promising approach for methionine reduction with potential utility for the treatment of HCU.

Indexed as

HomocystinuriaMethionineAnimalsDisease Models, AnimalEscherichia coliHealthy VolunteersHomocysteineHumansMiceRacemethionineHomocysteineMethionineRacemethionineclinical developmentdietary restrictionEscherichia coli Nisslehealthy volunteershomocystinuriainborn error of metabolismmethioninemousenonhuman primatessynthetic biotics

Identifiers

PMID38309259
OpenAlexW4391470437

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.